DL

Daniel Levy

IN Incyte: 12 patents #70 of 356Top 20%
GI Glycomed Incorporated: 7 patents #8 of 52Top 20%
PM Ptc Therapeutics Mp: 7 patents #1 of 11Top 10%
SP Signpath Pharma: 3 patents #4 of 20Top 20%
UF University of Florida Foundation: 2 patents #139 of 807Top 20%
The Johns Hopkins University: 2 patents #1,071 of 4,416Top 25%
PH Photogenesis: 1 patents #3 of 7Top 45%
MP Millennium Pharmaceuticals: 1 patents #496 of 771Top 65%
Overall (All Time): #91,580 of 4,157,543Top 3%
36
Patents All Time

Issued Patents All Time

Showing 25 most recent of 36 patents

Patent #TitleCo-InventorsDate
12421197 Aminopyrazine derivatives as PI3K-γ inhibitors Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +6 more 2025-09-23
12325706 Polymorphic form of sepiapterin Hiroshi Yoshino, Taichi Komoda, Yuichi Shiro, Shunichi Murata, Takayoshi MATSUMOTO +1 more 2025-06-10
12269829 Polymorphs of sepiapterin and salts thereof 2025-04-08
12213982 Pharmaceutical compositions comprising sepiapterin and uses thereof 2025-02-04
12173006 Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor Brent Douty, David M. Burns, Andrew P. Combs, Zhongjiang Jia, Eddy W. Yue 2024-12-24
12030885 Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh +5 more 2024-07-09
11926630 Tertiary alcohols as PI3K-γ inhibitors Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +7 more 2024-03-12
11780840 Tricyclic urea compounds as JAK2 V617F inhibitors Yanran Ai, Onur Atasoylu, Yu Sheng Bai, Joseph Barbosa, David M. Burns +11 more 2023-10-10
11773097 Polymorphs of sepiapterin and salts thereof 2023-10-03
11752154 Pharmaceutical compositions comprising sepiapterin and uses thereof 2023-09-12
11746119 Cardiopathy-reducing phosphodiester lipids James D. McChesney, Annie Bouchard, Saravanan Kappusamy, John Kallikat Augustine 2023-09-05
11661422 Tricyclic urea compounds as JAK2 V617F inhibitors Kai Liu, Brent Douty, Liangxing Wu, Wenqing Yao, Eddy W. Yue 2023-05-30
11643424 Cardiopathy-reducing phosphodiester lipids James D. McChesney, Annie Bouchard, Saravanan Kappusamy, John Kallikat Augustine 2023-05-09
11325908 CaMKII inhibitors and uses thereof Howard Schulman, Bheema R. Paraselli, Nangunoori Sampath Kumar, Brahmaiah Dabbugoddu, Chundru Balasubramanyam 2022-05-10
11225486 Tertiary alcohols as PI3K-γ inhibitors Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +7 more 2022-01-18
11186580 Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor Brent Douty, David M. Burns, Andrew P. Combs, Zhongjiang Jia, Eddy W. Yue 2021-11-30
11130760 Polymorphic form of sepiapterin Hiroshi Yoshino, Taichi Komoda, Yuichi Shiro, Shunichi Murata, Takayoshi MATSUMOTO +1 more 2021-09-28
11072614 Polymorphs of sepiapterin and salts thereof 2021-07-27
11046658 Aminopyrazine derivatives as PI3K-γ inhibitors Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +6 more 2021-06-29
10975088 Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh +5 more 2021-04-13
10975111 Cardiopathy-reducing phosphodiester lipids James D. McChesney, Annie Bouchard, Saravanan Kappusamy, John Kallikat Augustine 2021-04-13
10759792 CaMKII inhibitors and uses thereof Howard Schulman, Bheema R. Paraselli, Nangunoori Sampath Kumar, Brahmaiah Dabbugoddu, Chundru Balasubramanyam 2020-09-01
10738057 Tertiary alcohols as PI3K-γ inhibitors Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +7 more 2020-08-11
10479795 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh +5 more 2019-11-19
10081633 Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof Patricio Abarzua 2018-09-25